Version May 2024
| 5-year recurrence risk | Type and stage | Time interval to transplant |
| Low risk <5% risk of recurrence | Stage IA/IB, grade 1 to 2 endometrial cancer without lymph-vascular space invasion | No waiting period after completion of primary treatment |
| Stage IA/IB/IC grade 1 to 2 epithelial ovarian cancer | ||
| Stage IA1, IA2 squamous/adenocarcinoma of the cervix | ||
| Intermediate risk 5 to 15% risk of recurrence | Stage I/II endometrial cancer +risk factors* | 2 to 3 years after completion of treatment |
| Stage IB squamous/adenocarcinoma of the cervix | ||
| High risk >30% risk of recurrence | Serous, clear cell, or carcinosarcoma of uterus (all stages) | 5 years after completion of treatment |
| Stage III grade 1 to 3 endometrioid cancer of the uterus | ||
| Stage II/III epithelial ovarian cancer | ||
| Stage II/III squamous cell/adenocarcinoma cervical cancer | ||
| Very high risk >80% risk of recurrence | Stage IV endometrial cancer (all grades) | Not a SOT candidate |
| Recurrent or metastatic endometrial cancer | ||
| Stage IV epithelial ovarian cancer (any grade) | ||
| Recurrent ovarian cancer | ||
| Stage IV squamous cell/adenocarcinoma of the cervix | ||
| Metastatic or recurrent cervical cancer |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
